Technology Development Recent Happenings

Inventors Recognition Program

United States Patent 9,771,428 was issued on September 26, 2017 for CD47 targeted therapies for the treatment of infectious disease .  NIAID inventors: Kim Hasenkrug, Ph.D.

United States Patent 9,775,895 was issued on October 3, 2017 for HIV therapeutics and methods of making and using same.  NIAID inventor: Paolo Lusso, M.D., Ph.D.

United States Patent  9,783,596  was issued on October 10, 2017, for Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use.  NIAID inventor: Robert Purcell, M.D., (retired).

United States Patent 9,795,662 was issued on October 24, 2017 for Vaccine comprising AMA1 and RON2.   NIAID inventors: Prakash Srinivasan, Ph.D., Louis Miller, M.D.

Recent Patents

United States patent 9,845,350 was issued on December 19, 2017 for Monoclonal antibodies that react with the capsule of bacillus anthracis NIAID inventors:, Zhaochun Chen, Ph.D., Joanna Kubler-Kielb, Ph.D.

United States patent 9,850,468 was issued on December 26, 2017, for Infectious hepatitis E virus genotype 3 recombinants. NIAID inventors: Hanh T. Nguyen

United States patent, 9,580,492 was issued on January 30, 2018 for Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor.  NIAID inventor: Stephen Leppla, Ph.D.

United States patent 9,884,104 was issued on February 6, 2018 for Live attenuated virus vaccines for la crosse virus and other bunyaviridae.  NIAID inventors: Stephen S. Whitehead, Ph.D.Richard S. Bennett, Ph.D.

United States patent 9,896,509 was issued on February 20, 2018 for Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin  NIAID inventors: James Arthos, Ph.D.,  Claudia Cicala, Ph.D., Anthony S. Fauci, M.D.

 

Recent Collaborative Agreements

NIAID, BIONTECH and TRON entered into a research collaboration agreement (RCA) to construct RNA-based Epstein-Barr virus (EBV) vaccines.  NIAID principle investigator: Jeffery Taubenberger, M.D., Ph.D.

NIAID and Mymetics entered into a research collaboration agreement (RCA) to produce purified, well-characterized Pfa230 proteins for use in preparation of a virosome formulation.  NIAID principle investigator: Patrick Duffy, Ph.D.

NIAID and RNAceuticals entered into a research collaboration agreement (RCA) on the development and evaluation of N6-expressing replicon vectors.  NIAID principle investigator: Mark Connors, MD

NIAID and Case Western Reserve University (CRWU) School of Medicine entered into a human research collaboration agreement (hu-RCA) and NIAID will provide data generated to CWRU. NIAID principle investigator: Cathryn Haigh, Ph.D.

NIAID and the Seattle Children's Research Institute (SCRI) entered into a research collaboration agreement (RCA) to independently develop anti-HIV Chimeric Antigen Receptor (CAR) constructs and will conduct side-by-side comparisons of their respective constructs.  NIAID principle investigator: Edward Berger, Ph.D.

NIAID and Marshfield Clinic Research Institute, VRC, University of Wisconsin, and the University of Pennsylvania entered into a human research collaboration agreement (hu-RCA) to conduct studies to address the immune imprinting through a prospective serologic study of children who had PCR-confirmed influenza A infection in early childhood. NIAID principle investigator: Adrian McDermott, Ph.D.

NIAID and Synthetic Genomics Vaccines entered into a research collaboration agreement (RCA) to Evaluate novel alphavirus- or arterivirus-based replicons for their potential to serve as vaccine platforms against arenaviruses and filoviruses.  NIAID principle investigator: Dr. Peter Jahrling

NIAID and University of Colorado Denver School of Medicine entered into a human research collaboration agreement (hu-RCA) to collaborate on the Human Trisome Project. NIAID principle investigator: Michail Lionakis, M.D., Sc.D.

NIAID and San Diego Biomedical Research Institute entered into a research collaboration agreement (RCA) to generate virus-like particles (VLPs). NIAID principle investigator: Dr. Paolo Lusso

NIAID and Impact Biologicals Inc. entered into a research collaboration agreement (RCA) to better define conditions for manufacture and storage of correctly-folded recombinant alpha-synuclein.  NIAID principle investigator: Dr. Byron Caughey

NIAID and Scripps Research Institute (TSRI) entered into a research collaboration agreement (RCA) to develop a universal influenza vaccine through characterization of neutralizing antibody-hemagglutinin structure.  NIAID principle investigator: Ian Wilson, Ph.D.

Content last reviewed on March 26, 2018